LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | SB590885 | 0.04 | uM | LJP5 | 72 | hr | 1311 | 5029 | 5013 | 1.0032 | 1.0043 |
MDA-MB-231 | PIK-93 | 0.04 | uM | LJP5 | 72 | hr | 1311 | 5214 | 5013 | 1.0401 | 1.0543 |
MDA-MB-231 | KIN001-043 | 0.04 | uM | LJP6 | 72 | hr | 1311 | 4772 | 5013 | 0.9518 | 0.9348 |
MDA-MB-231 | Alpelisib | 0.04 | uM | LJP5 | 72 | hr | 1311 | 5183 | 5013 | 1.0339 | 1.0460 |
MDA-MB-231 | Luminespib | 0.04 | uM | LJP5 | 72 | hr | 1311 | 1013 | 5013 | 0.2021 | -0.0806 |
MDA-MB-231 | A443654 | 0.04 | uM | LJP6 | 72 | hr | 1311 | 3906 | 5013 | 0.7791 | 0.7008 |
MDA-MB-231 | OSI-027 | 0.04 | uM | LJP6 | 72 | hr | 1311 | 5123 | 5013 | 1.0218 | 1.0296 |
MDA-MB-231 | XMD11-85h | 0.04 | uM | LJP6 | 72 | hr | 1311 | 3815 | 5013 | 0.7609 | 0.6762 |
MDA-MB-231 | HG-6-64-01 | 0.04 | uM | LJP6 | 72 | hr | 1311 | 4569 | 5013 | 0.9115 | 0.8801 |
MDA-MB-231 | WH-4-025 | 0.04 | uM | LJP5 | 72 | hr | 1311 | 4389 | 5013 | 0.8755 | 0.8314 |
MDA-MB-231 | WZ-4-145 | 0.04 | uM | LJP6 | 72 | hr | 1311 | 4364 | 5013 | 0.8705 | 0.8246 |
MDA-MB-231 | XMD16-144 | 0.04 | uM | LJP5 | 72 | hr | 1311 | 2681 | 5013 | 0.5348 | 0.3699 |
MDA-MB-231 | Brivanib | 0.04 | uM | LJP5 | 72 | hr | 1311 | 5226 | 5013 | 1.0424 | 1.0574 |
MDA-MB-231 | Buparlisib | 0.04 | uM | LJP5 | 72 | hr | 1311 | 5265 | 5013 | 1.0502 | 1.0679 |
MDA-MB-231 | BX-912 | 0.04 | uM | LJP5 | 72 | hr | 1311 | 4614 | 5013 | 0.9203 | 0.8921 |
MDA-MB-231 | Canertinib | 0.04 | uM | LJP6 | 72 | hr | 1311 | 5102 | 5013 | 1.0178 | 1.0241 |
MDA-MB-231 | Celastrol | 0.04 | uM | LJP6 | 72 | hr | 1311 | 5141 | 5013 | 1.0254 | 1.0344 |
MDA-MB-231 | CGP60474 | 0.04 | uM | LJP5 | 72 | hr | 1311 | 3853 | 5013 | 0.7685 | 0.6865 |
MDA-MB-231 | CGP60474 | 0.04 | uM | LJP6 | 72 | hr | 1311 | 927 | 5013 | 0.1850 | -0.1038 |
MDA-MB-231 | CHIR-99021 | 0.04 | uM | LJP6 | 72 | hr | 1311 | 4664 | 5013 | 0.9304 | 0.9057 |
MDA-MB-231 | CP724714 | 0.04 | uM | LJP5 | 72 | hr | 1311 | 4619 | 5013 | 0.9214 | 0.8936 |
MDA-MB-231 | CP466722 | 0.04 | uM | LJP5 | 72 | hr | 1311 | 5276 | 5013 | 1.0524 | 1.0710 |
MDA-MB-231 | Crizotinib | 0.04 | uM | LJP5 | 72 | hr | 1311 | 4251 | 5013 | 0.8480 | 0.7941 |
MDA-MB-231 | Momelotinib | 0.04 | uM | LJP5 | 72 | hr | 1311 | 4666 | 5013 | 0.9307 | 0.9061 |
MDA-MB-231 | Dasatinib | 0.04 | uM | LJP5 | 72 | hr | 1311 | 2371 | 5013 | 0.4731 | 0.2863 |